The clinical efficacy of different treatments for macular edema secondary to BRVO

Abstract

Objective: To assess the clinical efficacy of sustained-release dexamethasone (DEX) , conbercept and laser photocoagulation on macular edema （ME） secondary to BRVO.Methods: 159 ischemic BRVO eyes were enrolled and randomly divided into sustained-release DEX group (30 eyes), CBC group (51 eyes), combination group (DEX+CBC, 29 eyes), and laser group (49 eyes). and received single intravitreal injection of sustained-release DEX (0.7 mg), CBC (0.05 ml) [3+PRN], sustained-release DEX (0.7 mg) combined with CBC (0.05 ml), and laser photocoagulation therapy respectively. The changes of the central foveal thickness (CFT) and best-corrected visual acuity (BCVA) were observed. Additionally, the number of HRD was calculated.Results: After treatment, CFT significantly decreased and BCVA significantly increased in DEX, CBC and combination groups (all P<0.01). Moreover, the number of HRD in three intravitreal injection groups was significantly reduced compared with pre-treatment (all P<0.01).Conclusion: Intravitreal injection of sustained-release DEX, CBC and combined treatment could alleviate BRVO-related ME, reduce CFT , and improve patients’ visual acuity . The retinal HRD number decreased after all intravitreal injections . In addition, there were non-responders in all intravitreal treatment groups, and the mean baseline HRD number of non-responder group was higher than that of responder group.